DocumentMolMeduploaded by
social_molmed- DocumentMolMed Rafforzamento Del Governo Societariouploaded bysocial_molmed
- DocumentMolMed NGR-hTNF mesothelioma, oral presentation at ASCO 2015uploaded bysocial_molmed
- DocumentMolMed NGRhTNF ASCO New Data Show Significantly Extended Survivaluploaded bysocial_molmed
- DocumentNuovi Dati Presentati Ad ASCO Su NGR-hTNF Incremento Sopravvivenza Globaleuploaded bysocial_molmed
- DocumentMolMed TK ASCO New Data From the Pivotal Phase III Randomized Trial TK008uploaded bysocial_molmed
- DocumentMolMed TK ASCO nuovi dati dello studio randomizzato registrativo Fase III TK008uploaded bysocial_molmed
- DocumentMolMed reports top line results of NGR-hTNF in the phase III trial in malignant pleural mesotheliomauploaded bysocial_molmed
- DocumentMolMed annuncia i risultati di NGR-hTNF nello studio di Fase III nel mesotelioma pleurico malignouploaded bysocial_molmed
- DocumentTK submission for Conditional Approval validated by EMAuploaded bysocial_molmed
- DocumentL'EMA ha validato la sottomissione della domanda di Conditional Approval per TKuploaded bysocial_molmed
- DocumentMolMed TK therapy submitted for Conditional Marketing Authorisation in EUuploaded bysocial_molmed
- DocumentMolMed deposita domanda di Conditional Marketing Authorisation in Europa per la terapia TKuploaded bysocial_molmed
- DocumentMolMed Approved The Interim Financial Report At 30 September 2013uploaded bysocial_molmed
- DocumentMolMed Approvato Resoconto Intermedio Gestione 30 Settembre 2013uploaded bysocial_molmed
- DocumentMolMed expands in the United States the Phase III trial of TK for the treatment of high-risk leukaemiauploaded bysocial_molmed
- DocumentFase III TK Stati Unitiuploaded bysocial_molmed
- DocumentMolMed NGR-hTNFuploaded bysocial_molmed
- DocumentLuigi Roth Presidente Terna Eletto Presidente Gruppo Lombardo Federazione Nazionale Cavalieri Del Lavorouploaded bysocial_molmed
- DocumentEuropean Cancer Congress, MolMed on efficacy of drug NGR-hTNFuploaded bysocial_molmed
- DocumentEuropean Cancer Congress MolMed Nuovi Dati Su NGR hTNF Aumento Sopravvivenza Nei Sarcomiuploaded bysocial_molmed
- DocumentEuropean Cancer Congress MolMed Su Farmaco Sperimentale NGR-hTNFuploaded bysocial_molmed
- DocumentMolMed Outcome of Shareholders' Meeting and Meeting Ff Board of Directorsuploaded bysocial_molmed
- DocumentMolMed Assemblea Azionistiuploaded bysocial_molmed
- DocumentMolMed official notification from the European Patent Office for NGR-hTNFuploaded bysocial_molmed
- DocumentUfficio Europeo Brevetti MolMed Nuovo Brevetto Per Biofarmaco Antitumorale NGR-hTNFuploaded bysocial_molmed
- DocumentMolMed NGR-hTNFuploaded bysocial_molmed
- DocumentIl Consiglio Di Amministrazione Di MolMed Approva La Relazione Finanziaria Semestrale Al 30 Giugno 2013uploaded bysocial_molmed
- DocumentMolMed TKuploaded bysocial_molmed
- DocumentMolMed ASCO 2013uploaded bysocial_molmed
- DocumentMolMed TK ASCO Sicurezza e sopravvivenza a lungo termine con TKuploaded bysocial_molmed
- DocumentMolMed NGR-hTNFuploaded bysocial_molmed
- DocumentMolMed NGR-hTNF four studies accepted for presentation at ASCO 2013uploaded bysocial_molmed
- DocumentMolMed TKuploaded bysocial_molmed
- DocumentAggiornamento sviluppo clinico dei prodotti MolMeduploaded bysocial_molmed
- DocumentCdA MolMed approva resoconto intermedio di gestione al 31 marzo 2013uploaded bysocial_molmed
- DocumentMolMeduploaded bysocial_molmed
- DocumentMolMeduploaded bysocial_molmed
- DocumentMolMeduploaded bysocial_molmed
- DocumentMolMeduploaded bysocial_molmed
- DocumentMolMed TKuploaded bysocial_molmed
- DocumentMolmed (TK)uploaded bysocial_molmed
- DocumentMolMed TKuploaded bysocial_molmed
- DocumentMolMeduploaded bysocial_molmed
- DocumentMolMed TK BMTuploaded bysocial_molmed
- DocumentMolMeduploaded bysocial_molmed
- DocumentMolMed NGR-hTNFuploaded bysocial_molmed
- DocumentMesotelioma recidivanteuploaded bysocial_molmed
- DocumentMolmed TK ASHuploaded bysocial_molmed
Professional Documents
Culture Documents
